Prognostic value of serum uric acid levels following radiotherapy and chemotherapy in nasopharyngeal carcinoma

Read full text
Authors: X. He, Qiwei Luo, Yi Ding, Jianwu Ding, Ronghuan Hu, Jia-Li Hu, Lei Tao, J X Zhang, Zhenxing Huang, Xiaoqiang Chen, Jiayin Wu, Su Deng
+3 more Shubin Luo, Lei Zeng, Mengmeng Liu
Cited by: 0

Abstract

To evaluate the association between serum uric acid (SUA) levels and prognosis in patients with nasopharyngeal carcinoma (NPC) treated with a comprehensive regimen of induction chemotherapy, intensity-modulated radiation therapy (IMRT), and adjuvant chemotherapy. A total of 182 patients with NPC treated at the Second Affiliated Hospital of Nanchang University between 2017 and 2021 were retrospectively analyzed. SUA levels were recorded at four time points: Pre-treatment, post-induction chemotherapy, post-IMRT and post-adjuvant chemotherapy. Based on the median post-adjuvant chemotherapy SUA level (350.48 µmol/l), patients were stratified into high (SUA >350 µmol/l) and low (SUA ≤350 µmol/l) groups. Survival outcomes were compared using Kaplan-Meier analysis and log-rank tests. Cox proportional hazards models were employed to identify independent prognostic factors. Changes in SUA levels over time were assessed using repeated-measures ANOVA. The high SUA group demonstrated improved 3-year overall survival (OS; P=0.037), progression-free survival (PFS; P

Fields of Study & Subjects

Head and Neck Cancer Studies Gout Hyperuricemia Uric Acid Inflammatory Biomarkers in Disease Prognosis

Publication details

Journal / source
Molecular and Clinical Oncology
Volume
24
Issue
2
Pages
1–10
Publication date
8 January 2026
Language
EN